James Voos, MD, chair of the Department of Orthopedics and Sports Medicine at University Hospitals Cleveland Medical Center, Cleveland Browns team physician, and president of the NFL Physicians Society (NFLPS), shares his goals for the society and offers insight into how he is using biotechnology to monitor recovery, prevent further injuries, and safely return athletes to competition.

James Voos, MD, president of the NFL Physicians Society (NFLPS), discusses the society's efforts to standardize care for NFL players across the league in an interview with SmartTRAK at the American Orthopaedic Society for Sports Medicine (AOSSM) 2025 Annual Meeting recently held in Nashville, TN.

Dr. Voos also shares an update on ongoing clinical research for osteoarthritis treatment with stem cells. To listen to the interview, please click on the following video (4:18 minutes). A link to download a complete transcript of the interview is alsoprovided below. 

SmartTRAK: Hi, this is Dave Shepard. I'm here at the AOSSM 2025. Keep watching for my interview with Dr. James Voos, who is the team physician for the Cleveland Browns, and also the president of the NFL Physicians’ Society. Dr. Voos, thanks for joining us.

James Voos, MD: Thank you very much for the invitation. I appreciate it.

Excellent. Tell me a little bit about the NFL PS and a little bit about what you're doing, what your initiatives are, what your goals are.

JV: As president of the NFL Physician Society, we represent all of the physicians that provide care for our professional athletes in football. That's not only our orthopedic surgeons, but our medical physicians and all of our associated consultants. So we help to provide standards for how to practice across the league, and that way we assure that every athlete and every team has ...

Interested in how biotechnology can be used to monitor recovery, prevent further injuries and safely return athletes to competition? Click
the button below to download the full transcript of SmartTRAK GM/Sr Analyst David Shepard's interview of James Voos, MD, president of the NFL Physicians Society (NFLPS) from AOSSM 2025.

In this comprehensive article, SmartTRAK provides an overview of the WISeR Model and its potential market impact on skin substitutes.

Click the button below to download and read the complete article "Skin Substitutes Get WISeR – Will it Impact the Market?" by Jay Merkel, SmartTRAK Sr Analyst, Wound.

Nearly half a billion in US dollars has been invested in Advanced Wound Care over the last 18 months. Learn where the money is going.

Over the past three years the global Advanced Wound Care Market has almost doubled, an exciting market for investment according to SmartTRAK estimates. The biggest deal in Advanced Wound Care (AWC) has been Coloplast's acquisition of Kerecis in 2023. Kerecis, a startup in the US Skin Substitute Market, demonstrated strong growth and the potential to have a global presence, justifying the high price. Startups have been a key component of the market, with new technologies and products over the years, and have been advancing their portfolios through IPOs, strategic partnerships, and investments. 

This downloadable article reviews the recent top deals and investment trends in AWC, including:

• Recent Global Wound Care Investments
  • Top Deals and Investments Jan 2024 through June 2025
• Market Trends
  • Although the US Skin Substitute/ CAMPs Market has seen exponential growth in the last few years, that isn't where global investment is occurring.
• Investment by Geography
  • US and Canada Wound Care Investments
  • UK, Europe, and Rest of World (ROW)
• Early-Stage Investments
  • Non-Dilutive Funding Sources
  • Strategic and Insurance Provider Investments

Want to know which deals are shaping the future of wound care? Click below to download the full article, “Deals in Advanced Wound Care,” co-authored by Dr. Mitchell C. Sanders, CEO, ProDevLabs and Susan Paquette, SmartTRAK Senior Advisor, Wound, to get a firsthand look at the key investment trends driving this dynamic market.

Nitric Oxide (NO) has numerous benefits for wound healing but has challenges associated with its delivery. Several companies are addressing those challenges and creating an exciting opportunity in wound care.

Nitric oxide (NO) was named “Molecule of the Year” by the journal Science in 1992, and six years later, three US scientists were awarded the Nobel Prize for Physiology and Medicine for their efforts to prove that NO, an endogenous gas and free radical, could have crucial biological effects. One of the well-known medical uses of NO is via nitroglycerin, a precursor to NO, to prevent and treat chest pain (angina). It works by relaxing blood vessels, which decreases the amount of work the heart has to do. NO has been identified for its value in chronic wound healing for many years because of its function in vasodilation, relaxing blood vessels and increasing blood flow, as well as its broad-spectrum antimicrobial and antibiofilm activity.

No products have yet reached the market for chronic wounds; however, SmartTRAK has noted increasing activity related to the benefits of NO for wound healing. In fact, an article was published earlier this year entitled “Emerging Strategies for Nitric Oxide Production and Their Topical Application as Nano Dressings to Promote Diabetic Wound Healing.” The article identified four primary modes in which NO benefits the diabetic wound healing process: providing antimicrobial properties, promoting angiogenesis, regulating inflammation and promoting tissue regeneration and remodeling.

This market outlook article will discuss in detail the following subjects:

Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of delay and how industry players may choose to react.

On April 11, 2025, Centers for Medicare and Medicaid Services announced that the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers Final Local Coverage Determinations (LCDs) effective date will be delayed until January 1, 2026. In this video (16:43 minutes), SmartTRAK Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of delay, and how industry players may choose to react.

The SmartTRAK Wound Team will be in attendance at the upcoming SAWC Spring conference in Grapevine, TX (April 30 to May 4). Please register here to meet the team.

• Expanding Reimbursement for Lymphedema Products 
  • One of the biggest growth drivers for compression therapies in 2025 is expanding reimbursement for the treatment of lymphedema. With more than three million lymphedema patients estimated in the US alone, SmartTRAK expects ... (read more)
• Improving Ease of Use for Compression Garments
  • SmartTRAK expects several companies to develop or refine compression garments in the years ahead with a focus on improving ease of use. With the growing number of patients having access to compression garments day and night, it’s become even more important for ... (read more)
• Dynamic Compression Innovations Improving Portability
  
  • In the world of dynamic compression, portability is the name of the game and SmartTRAK expects to see ... (read more)

Want to stay ahead of the curve in the US compression device market for 2025 and beyond? Industry trends, regulatory changes and new reimbursement codes are shaping the future—are you prepared?

Click the button below to download Jay Merkel’s market outlook article, "Feel the Pressure: Compression Trends for 2025." As SmartTRAK’s senior analyst, Wound, Jay provides an informative analysis of the latest market shifts, including new compression codes and major code revisions set to take effect on April 1, 2025.